Skip to content
Helping patients reclaim a life of possibility
Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE

What we do

  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
      • AL amyloidosis vs myeloma
      • Living with AL amyloidosis
      • Diagnosis, treatment and monitoring of AL amyloidosis
      • CAR T-cell therapy side effects
      • Minimal Residual Disease (MRD)
      • Chimeric Antigen Receptor T cell (CAR-T) therapy
      • SARS-CoV-2 (COVID-19) Vaccination and Treatment
      • European Union (EU) Funded Projects
      • Health Technology Assessment (HTA)
      • H2020 MMPredict
    • Toolkits
    • Factsheets
      • Melphalan flufenamide
      • Teclistamab
      • Ciltacabtagene autoleucel
      • Idecabtagene vicleucel
      • Isatuximab
      • Selinexor
      • Thalidomide
      • Lenalidomide
      • Pomalidomide
      • Bortezomib
      • Daratumumab
      • Panobinostat
      • Elotuzumab
      • Ixazomib
      • Carfilzomib
      • Amyloidosis
      • Belantamab mafodotin
      • Stem cell transplant
    • Patient guides

Subscribe to
our newsletter!

Subscribe here

Webinars

Recording of the webinar ‘How do different countries make decisions on reimbursing new medicines?’ held by MPE on 2nd April 2025, and given by Tom Belleman, PhD candidate at the Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam.

The webinar was held as part of the Horizon Europe ASCERTAIN, an EU funded project working to promote access to medicines through the development of open access policy tools, including pricing and value assessment models.
Prev 1 of 5 Next
  • Webinar | ‘How do different countries make decisions on reimbursing new medicines?’

    Webinar | ‘How do different countries make decisions on reimbursing new medicines?’

  • Webinar EYMPG | Myeloma and physical fitness

    Webinar EYMPG | Myeloma and physical fitness

  • MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

    MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

  • Webinar EYMPG | Importance of good nutrition and healthy diet for young myeloma patients

    Webinar EYMPG | Importance of good nutrition and healthy diet for young myeloma patients

  • MPE webinar | Disease and treatment specificities for young myeloma patients

    MPE webinar | Disease and treatment specificities for young myeloma patients

  • MPE Webinar | EHA 2024 myeloma highlights

    MPE Webinar | EHA 2024 myeloma highlights

  • MPE and ALAN webinar | Patient and clinician involvement in the EU HTA regulation

    MPE and ALAN webinar | Patient and clinician involvement in the EU HTA regulation

  • MPE/ALAN Webinar | EU HTA

    MPE/ALAN Webinar | EU HTA

  • MPE webinar | AL amyloidosis treatment updates and patient experiences

    MPE webinar | AL amyloidosis treatment updates and patient experiences

  • Webinar | Basics of medicines pricing in Europe

    Webinar | Basics of medicines pricing in Europe

  • European Young Myeloma Patients Group launch event

    European Young Myeloma Patients Group launch event

  • MPE Webinar ASH 2023 myeloma and AL amyloidosis highlights

    MPE Webinar ASH 2023 myeloma and AL amyloidosis highlights

Prev 1 of 5 Next
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Commitee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month 2025
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.